Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MLLT1 | Q03111 | 2/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.51 |
| ▸ | HTT | P42858 | 2/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 3/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | CACNA1G | O43497 | 2/20 | 0.43 |
| ▸ | CDC7 | O00311 | 1/20 | 0.43 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.43 |
| ▸ | DBF4 | Q9UBU7 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL50840 | 0.99 | MLLT1 (0.50) | MLLT1KDM4EHTTHSD17B10ALDH1A1 | |
| SCHEMBL3518675 | 0.91 | MLLT1 (0.44) | MLLT1KDM4EHTTHSD17B10ALDH1A1 | |
| SCHEMBL3517823 | 0.90 | MEN1 (0.43) | MLLT1KDM4EHTTHSD17B10ALDH1A1 | |
| SCHEMBL3519685 | 0.89 | SMN1; SMN2 (0.43) | MLLT1HTTHSD17B10ALDH1A1GAA | |
| SCHEMBL61188 | 0.81 | TNKS2 (0.50) | KDM4EHSD17B10ALDH1A1HPGDGAA | |
| SCHEMBL51858 | 0.81 | KDM4E (0.41) | KDM4EHSD17B10ALDH1A1HPGDGAA | |
| SCHEMBL3520029 | 0.80 | KDM4E (0.45) | KDM4EHSD17B10ALDH1A1HPGDGAA | |
| SCHEMBL3515927 | 0.80 | KDM4E (0.40) | KDM4EHSD17B10ALDH1A1HPGDGAA | |
| SCHEMBL50996 | 0.78 | KMT2A (0.41) | KDM4EHSD17B10ALDH1A1HPGDGAA | |
| SCHEMBL14550565 | 0.78 | GAA (0.45) | KDM4EHSD17B10ALDH1A1HPGDGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120309717-A1 | COMPOUNDS, METHODS AND PHARMACEUTICAL COMPOSITIONS FOR INHIBITING PARP | EISAI INC. (US) | 2012-12-06 | — | — | US | disclosed |
| EP-1633362-B1 | COMPOUNDS, METHODS AND PHARMACEUTICAL COMPOSITIONS FOR INHIBITING PARP | EISAI INC (US) | 2012-09-26 | — | — | EP | disclosed |
| US-8129382-B2 | Compounds, methods and pharmaceutical compositions for inhibiting PARP | EISAI INC. (US) | 2012-03-06 | — | — | US | disclosed |
| US-20100256095-A1 | COMPOUNDS, METHODS AND PHARMACEUTICAL COMPOSITIONS FOR INHIBITING PARP | EISAI INC. (US) | 2010-10-07 | — | — | US | disclosed |
| US-7750008-B2 | Compounds, methods and pharmaceutical compositions for inhibiting PARP | EISAI INC. (US) | 2010-07-06 | — | — | US | disclosed |
| US-20090298837-A1 | poly(ADP-ribose) polymerase (PARP) inhibitors such as 9-[(Hydrozinooxy)carbonyl]-2,7-dihydro-6-methoxy 3H-pyrido-[4,3,2-de]phthalazin-3-one, used for treating neuron tissue damage resulting from ischemia and reperfusion injury, depression, inflammatory bowel disorders, arthritis, gout, pain and sepsis | EISAI CORPORATION OF NORTH AMERICA (US) | 2009-12-03 | — | — | US | disclosed |
| US-7601719-B2 | Administering temozolomide; poly/adp-ribose/polymerase (PARP) inhibitors; melanoma, lymphoma, glioblastoma multiforme | EISAI CORPORATION OF NORTH AMERICA (US) | 2009-10-13 | — | — | US | disclosed |
| US-20090088407-A1 | Administering temozolomide; poly/adp-ribose/polymerase (PARP) inhibitors; melanoma, lymphoma, glioblastoma multiforme | MGI GP, INC. (US) | 2009-04-02 | — | — | US | disclosed |
| US-7456178-B2 | Compounds, methods and pharmaceutical compositions for inhibiting PARP | MGI GP, INC. (US) | 2008-11-25 | — | — | US | disclosed |
| EP-1633362-A4 | COMPOUNDS, METHODS AND PHARMACEUTICAL COMPOSITIONS FOR INHIBITING PARP | MGI GP INC (US) | 2008-08-27 | — | — | EP | disclosed |
| US-20080058325-A1 | COMPOUNDS, METHODS AND PHARMACEUTICAL COMPOSITIONS FOR INHIBITING PARP | MGI GP, INC. (US) | 2008-03-06 | — | — | US | disclosed |
| US-7268138-B2 | Compounds, methods and pharmaceutical compositions for inhibiting PARP | MGI GP, INC. (US) | 2007-09-11 | — | — | US | disclosed |
| EP-1633362-A2 | COMPOUNDS, METHODS AND PHARMACEUTICAL COMPOSITIONS FOR INHIBITING PARP | MGI GP, Inc. (US) | 2006-03-15 | — | — | EP | disclosed |
| US-20050020595-A1 | Compounds, methods and pharmaceutical compositions for inhibiting PARP | EISAI INC. | 2005-01-27 | — | — | US | disclosed |
| WO-2004105700-A2 | COMPOUNDS, METHODS AND PHARMACEUTICAL COMPOSITIONS FOR INHIBITING PARP | GUILDFORD PHARMACEUTICALS, INC. (US) | 2004-12-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090298837-A1 | poly(ADP-ribose) polymerase (PARP) inhibitors such as 9-[(Hydrozinooxy)carbonyl]-2,7-dihydro-6-methoxy 3H-pyrido-[4,3,2-de]phthalazin-3-one, used for treating neuron tissue damage resulting from ischemia and reperfusion injury, depression, inflammatory bowel disorders, arthritis, gout, pain and sepsis | PARP1, PARP2, NLRP3 | MLLT1 1769/4885KDM4E 2880/4885HTT 234/4885 |
| US-20080058325-A1 | COMPOUNDS, METHODS AND PHARMACEUTICAL COMPOSITIONS FOR INHIBITING PARP | PARP1, PARP2, PARP3 | MLLT1 856/4885KDM4E 1640/4885HTT 998/4885 |
| US-20050020595-A1 | Compounds, methods and pharmaceutical compositions for inhibiting PARP | PARP1, PARP2, PARP3 | MLLT1 798/4885KDM4E 1571/4885HTT 1028/4885 |
| US-20120309717-A1 | COMPOUNDS, METHODS AND PHARMACEUTICAL COMPOSITIONS FOR INHIBITING PARP | PARP1, PARP2, PARP3 | MLLT1 798/4885KDM4E 1571/4885HTT 1028/4885 |
| US-20090088407-A1 | Administering temozolomide; poly/adp-ribose/polymerase (PARP) inhibitors; melanoma, lymphoma, glioblastoma multiforme | PARP1, PARP2, PARP11 | MLLT1 302/4885KDM4E 297/4885HTT 1534/4885 |
| US-20100256095-A1 | COMPOUNDS, METHODS AND PHARMACEUTICAL COMPOSITIONS FOR INHIBITING PARP | PARP1, PARP2, PARP3 | MLLT1 798/4885KDM4E 1571/4885HTT 1028/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.